<DOC>
	<DOC>NCT02739828</DOC>
	<brief_summary>The objective of this study is to assess quality of life (QoL), skin pain, work productivity/activity and health related problems in Swedish patients with moderate to severe HS before and after 6 months treatment with Adalimumab. The patients will be treated in accordance with normal routine clinical care.</brief_summary>
	<brief_title>Post Marketing Observational Study (PMOS) to Assess Quality of Life in Swedish Hidradenitis Suppurativa (HS) Patients</brief_title>
	<detailed_description />
	<mesh_term>Hidradenitis</mesh_term>
	<mesh_term>Hidradenitis Suppurativa</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<criteria>Diagnosis of Hidradenitis Suppurativa Prescribed Adalimumab according to the Summary of Product Characteristics (SmPC) Willingness to sign and date a Patient Information/Informed Consent Form Prior biologic treatment discontinued &lt;6 months before the baseline visit Patient not able to understand the language of the provided patient questionnaires History of noncompliance with medication or a medical history that could enhance noncompliance with medication, as determined by the investigator</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Quality of life</keyword>
</DOC>